US Lawmakers Target PBMs to Curb Drug Costs; Healthcare Stocks Face Regulatory Pressure

Prescription drug prices in the United States have reached unsustainable levels, prompting urgent calls for legislative intervention to curb rising costs. Proposed reforms are increasingly focusing on the role of Pharmacy Benefit Managers (PBMs), who are identified as a primary driver of price inflation due to their opaque business practices. Legislators aim to implement new laws that would limit the influence of these intermediaries and enhance transparency across the pharmaceutical supply chain. This regulatory shift poses a significant risk to major healthcare providers and insurers who rely on PBM operations for substantial revenue streams. Companies such as CVS Health (CVS), UnitedHealth (UNH), and Cigna (CI) could see their profit margins compressed if these reforms are enacted. Consequently, the broader healthcare sector, represented by the XLV ETF, may face increased volatility as the legislative process unfolds in Washington.